Related Experiment Videos

Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor

J Wang1, L Sun, L Myeroff

  • 1Department of Biochemistry and Molecular Biology, Medical College of Ohio, Toledo 43699, USA.

Insights

Restoring TGF-beta type II receptor (RII) expression in colorectal cancer cells reversed malignancy. This indicates that loss of RII function is a key driver of hereditary nonpolyposis colorectal cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Loss of TGF-beta type II receptor (RII) expression is linked to replication error (RER) colorectal cancer, a hallmark of hereditary nonpolyposis colorectal cancer.
  • RER-positive HCT 116 cells exhibited a frameshift mutation in RII due to a 1-base deletion in a polyadenine tract.

Purpose of the Study:

  • To investigate the role of TGF-beta type II receptor (RII) mutations in colorectal cancer malignancy.
  • To determine if restoring RII expression can reverse the malignant phenotype in RER colorectal cancer.

Main Methods:

  • Transfection of an RII expression vector into HCT 116 colon carcinoma cells.
  • Assessed mRNA and protein expression of RII, fibronectin levels, cell clonogenicity, saturation density, and tumorigenicity in athymic mice.
  • Utilized TGF-beta 1 treatment and TGF-beta 1-neutralizing antibodies to evaluate cellular responses.

Main Results:

  • RII transfectants expressed RII mRNA and protein, regained sensitivity to TGF-beta 1, and showed dose-dependent fibronectin mRNA induction.
  • Transfected cells exhibited reduced clonogenicity, lower saturation density, and growth arrest.
  • Tumorigenicity in mice was significantly reduced and delayed in RII-reconstituted cells, suggesting acquired autocrine-negative activity.

Conclusions:

  • Reconstitution of TGF-beta autocrine activity via RII reexpression reverses malignancy in RER colorectal cancers.
  • Loss of RII expression is a critical determinant of malignancy in hereditary nonpolyposis colorectal cancer.

Related Concept Videos